Serum BAFF strongly correlates with PsA activity in male patients only - Is there a role for sex hormones?

Clinical and Experimental Rheumatology

Volumn 28, Issue 6, 2010, Pages 813-819

  Pongratz, G ^a   Straub, R H ^a   Scholmerich J ^a   Fleck, M ^a,b   Harle P ^a,c  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b Department of Rheumatology/Clinical Immunology ^*  (Germany)

^c Catholic Clinic Mainz   (Germany)

Author keywords

BAFF BlyS; Estradiol; Gender difference; Psoriasis; Psoriatic arthritis; Testosterone

Indexed keywords

B CELL ACTIVATING FACTOR; ESTRADIOL; TESTOSTERONE; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ACTIVITY; ESTRADIOL BLOOD LEVEL; FEMALE; GENDER; HUMAN; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIATIC ARTHRITIS; TESTOSTERONE BLOOD LEVEL; B LYMPHOCYTE; BLOOD; COMPARATIVE STUDY; DISABILITY; HOSPITALIZATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; SEXUAL DEVELOPMENT; STATISTICAL MODEL;

ADULT; ARTHRITIS, PSORIATIC; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; BIOLOGICAL MARKERS; DISABILITY EVALUATION; ESTRADIOL; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SEX CHARACTERISTICS; TESTOSTERONE;

EID: 79952638913     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. VEALE D, YANNI G, ROGERS S, BARNES L, BRESNIHAN B, FITZGERALD O: Reduced synovial membrane macrophage numbers, ELAM-I expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum 1993; 36: 893-900.
2. PONGRATZ G, STRAUB RH: B-cell involvement in the pathogenesis of RA - is there a contribution of the sympathetic nervous system? Immunol Res 2008; 40: 148-63.
3. SILVERMAN GJ, BOYLE DL: Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: the B-cell roadblock hypothesis. Immunol Rev 2008; 223: 175-85.
4. CANETE JD, SANTIAGO B, CANTAERT T et al:. Ectopic lymphoid neogenesis in psoriatic arthritis. Ann Rheum Dis 2007; 66: 720-6.
5. TAKEMURA S, BRAUN A, CROWSON C et al.: Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001; 167: 1072-80.
6. WEYAND CM, GORONZY JJ: Ectopic germinal center formation in rheumatoid synovitis. Ann N Y Acad Sci 2003; 987: 140-9.
7. COHEN SB, EMERY P, GREENWALD MW et al:. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806.
8. SMOLEN JS, ALETAHA D, KOELLER M, WEISMAN MH, EMERY P: New therapies for treatment of rheumatoid arthritis. Lancet 2007; 370: 1861-74.
9. DASS S, VITAL EM, EMERY P: Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum 2007; 56: 2715-8.
10. SCHNEIDER P, MACKAY F, STEINER V et al:. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189: 1747-56.
11. STADANLICK JE, CANCRO MP: BAFF and the plasticity of peripheral B cell tolerance. Curr Opin Immunol 2008; 20: 158-61.
12. NARDELLI B, BELVEDERE O, ROSCHKE V et al.: Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001; 97: 198-204.
13. GROSS JA, JOHNSTON J, MUDRI S et al.: TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404: 995-9.
14. THOMPSON JS, BIXLER SA, QIAN F et al.: BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001;293:2108-11.
15. CHEEMA GS, ROSCHKE V, HILBERT DM, STOHL W: Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44: 1313-9.
16. Groom J, Kalled SL, Cutler AH et al.: Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002; 109: 59-68. (Pubitemid 34052542)
17. MACKAY F, WOODCOCK SA, LAWTON P et al:. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190: 1697-710.
18. DALL'ERA M, CHAKRAVARTY E, WALLACE D et al:. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, doubleblind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007; 56: 4142-50.
19. TAK PP, THURLINGS RM, ROSSIER C et al.: Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase lb, doubleblind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 2008; 58: 61-72.
20. TAYLOR W, GLADMAN D, HELLIWELL P, MARCHESONI A, MEASE P, MIELANTS H: Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-73.
21. PREVOO ML, VAN 'T HOF MA, KUPER HH, VAN LEEUWEN MA, VAN DE PUTTE LB, VAN RIEL PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longi-tudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
22. VAN DER HEIJDE DM, VAN 'T HM, VAN RIEL PL, VAN DE PUTTE LB: Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579-81.
23. FREDRIKSSON T, PETTERSSON U: Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
24. Fransen J, Antoni C, Mease PJ et al.: Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006; 65: 1373-8. (Pubitemid 44620449)
25. SUN J, LIN Z, FENG J, LI Y, SHEN B: BAFF-targeting therapy, a promising strategy for treating autoimmune diseases. Eur J Pharmacol 2008; 597: 1-5.
26. LOCKSHIN MD: Sex differences in autoimmune disease. Orthop Clin North Am 2006; 37: 629-33.
27. SCHMIDT M, NAUMANN H, WEIDLER C, SCHELLENBERG M.A. NDERS S, STRAUB RH: Inflammation and sex hormone metabolism. Ann N Y Acad Sci 2006; 1069: 236-46.
28. FARBER EM NL: Epidemiology: natural history and genetics. In: ROENIGK HH JR, (Eds.): Psoriasis. New York, Dekker, 1998: p.107-57.
29. REYES LI, LEON F, GONZALEZ P et al:. Dexamethasone inhibits BAFF expression in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Cytokine 2008; 42: 170-8.
30. ATZENI F, SARZI-PUTTINI P, DEPORTU S, CUTOLO M, CARRABBA M, STRAUB RH: In etanercept-treated psoriatic arthritis patients clinical improvement correlated with an increase of serum Cortisol relative to other adrenal hormones. Clin Exp Rheumatol 2008; 26: 103-8.
31. CUTOLO M, SERIOLO B, PIZZORNI C, SULLI A: The role of androgens in rheumatic diseases. Isr Med Assoc J 2001; 3: 743-8.
32. HOLZMANN H, BENES P, MORSCHES B, MATTHAEI D, STOHR L: (Psoriasis and haemodialysis: changes in plasma hormone concentration as a possible therapeutic mechanism (author's transl)). Dtsch Med Wochenschr 1981; 106: 1245-7.
33. CUTOLO M, SULLI A, PIZZORNI C, CRAVIOTTO C, STRAUB RH: Hypothalamic-pituitary-adrenocortical and gonadal functions in rheumatoid arthritis. Ann N Y Acad Sei 2003; 992: 107-17.
34. STRAUB RH, HARLE P, YAMANA S et al.: Anti-interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2006; 54: 1778-85.
35. SAMOUD-EL KS, GALAI Y, SGHIRI R et al:. BAFF is elevated in serum of patients with psoriasis: association with disease activity. Br J Dermatol 2008; 159: 765-8.